Top 10 Companies Shaping the Global Parathyroid Disorders Market (2026–2034)
According to a newly published market research report by 24LifeSciences, global parathyroid disorders market is valued at USD 2.1 billion in 2026 and is projected to reach USD 3.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period.
Parathyroid disorders are medical conditions resulting from the dysfunction of the parathyroid glands, four small glands located in the neck that regulate the body's calcium levels. These disorders lead to abnormal calcium levels in the blood, which can cause significant health issues such as brittle bones (osteoporosis), kidney stones, chronic fatigue, and muscle weakness. The primary disorders include hyperparathyroidism (overactive glands), hypoparathyroidism (underactive glands), and the rare parathyroid cancer.
Market growth is primarily driven by an aging global population more susceptible to these conditions and the rising prevalence of chronic kidney disease (CKD), a major cause of secondary hyperparathyroidism. Furthermore, advancements in diagnostic techniques, such as more sensitive parathyroid hormone (PTH) assays, are facilitating earlier and more accurate detection. Key players like Amgen, with its calcimimetic drug Cinacalcet, and Abbott Laboratories, a leader in diagnostic solutions, are actively shaping the treatment landscape through innovation and strategic initiatives, contributing to market expansion.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9574/parathyroid-disorders-market
According to a newly published market research report by 24LifeSciences, global parathyroid disorders market is valued at USD 2.1 billion in 2026 and is projected to reach USD 3.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period.
Parathyroid disorders are medical conditions resulting from the dysfunction of the parathyroid glands, four small glands located in the neck that regulate the body's calcium levels. These disorders lead to abnormal calcium levels in the blood, which can cause significant health issues such as brittle bones (osteoporosis), kidney stones, chronic fatigue, and muscle weakness. The primary disorders include hyperparathyroidism (overactive glands), hypoparathyroidism (underactive glands), and the rare parathyroid cancer.
Market growth is primarily driven by an aging global population more susceptible to these conditions and the rising prevalence of chronic kidney disease (CKD), a major cause of secondary hyperparathyroidism. Furthermore, advancements in diagnostic techniques, such as more sensitive parathyroid hormone (PTH) assays, are facilitating earlier and more accurate detection. Key players like Amgen, with its calcimimetic drug Cinacalcet, and Abbott Laboratories, a leader in diagnostic solutions, are actively shaping the treatment landscape through innovation and strategic initiatives, contributing to market expansion.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9574/parathyroid-disorders-market
Top 10 Companies Shaping the Global Parathyroid Disorders Market (2026–2034)
According to a newly published market research report by 24LifeSciences, global parathyroid disorders market is valued at USD 2.1 billion in 2026 and is projected to reach USD 3.5 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period.
Parathyroid disorders are medical conditions resulting from the dysfunction of the parathyroid glands, four small glands located in the neck that regulate the body's calcium levels. These disorders lead to abnormal calcium levels in the blood, which can cause significant health issues such as brittle bones (osteoporosis), kidney stones, chronic fatigue, and muscle weakness. The primary disorders include hyperparathyroidism (overactive glands), hypoparathyroidism (underactive glands), and the rare parathyroid cancer.
Market growth is primarily driven by an aging global population more susceptible to these conditions and the rising prevalence of chronic kidney disease (CKD), a major cause of secondary hyperparathyroidism. Furthermore, advancements in diagnostic techniques, such as more sensitive parathyroid hormone (PTH) assays, are facilitating earlier and more accurate detection. Key players like Amgen, with its calcimimetic drug Cinacalcet, and Abbott Laboratories, a leader in diagnostic solutions, are actively shaping the treatment landscape through innovation and strategic initiatives, contributing to market expansion.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9574/parathyroid-disorders-market
0 Kommentare
0 Anteile
55 Ansichten
0 Vorschau
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek